Project Grant R21AI181790
Award Date
8/1/24
Completion Date
6/30/26
Dollars Obligated
$234K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $624,902 to The University of Texas Health Science Center at San Antonio to investigate the role of the HIV accessory protein Vpr in facilitating viral persistence in myeloid cells. The research aims to characterize how Vpr induces epigenetic remodeling at HIV integration sites, which may reveal novel therapeutic...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,616.00 to Emory University to develop virus-like particles (VLPs) for an HIV-1 cure strategy. The key objectives are to: Use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent, paired with AAV vectors expressing broadly neutralizing antibodies to eliminate reactivated HIV-infected cells (the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $183,602 to The University of North Texas Health Science Center at Fort Worth to support research on engineering a simian-compatible version of HIV-1. The goal is to construct an "HSIV" virus, which has an HIV-1 backbone with minimal SIV gene fragments, to enable more effective studies of AIDS pathogenesis...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $681,278 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant, which runs from July 2024 to May 2026, will fund research to characterize the HIV latent reservoir and model the contributions of antigen-driven and homeostatic proliferation to its persistence in people living with HIV on antiretroviral therapy. The goal is to help design future HIV...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to elucidate the molecular mechanisms underlying T cell dysfunction and HIV persistence in persons with HIV (PWH). The $500,000 award, effective from September 1, 2024 to August 31, 2029, will support research conducted by The General Hospital Corporation (Massachusetts General Hospital) to identify and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $502,861 to the University of California, San Diego (UCSD) to investigate the role of the PCIF1 protein and its effects on RNA modification in the context of HIV infection. The key objectives are to: Define the dynamics and mapping of human m6Am RNA methylome in response to HIV infection and methamphetamine exposure....
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded $852,121.24 to The Scripps Research Institute-Florida under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period of July 22, 2021 through October 31, 2021. The project aims to identify host factors that regulate HIV latency and reactivation in order to develop strategies for durable HIV silencing. The grantee will define the roles of three identified host factors, P32,...
This $536,943.46 Project Grant from the National Institutes of Health National Institute of Allergy and Infectious Diseases funds research at The Scripps Research Institute-Florida on identifying host factors that regulate HIV latency and reactivation. The grant supports three aims over a six-month period: defining the roles of proteins P32, FUBP3, and PHB2 in HIV transcription and chromatin structure; investigating protein complexes associated with P32, FUBP3, and PHB2 and their interaction...
This Project Grant award for $1,314,572.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at developing a cure strategy for HIV-1 using CD4-mimetic compounds (CD4MCs) and CD4-induced antibodies (CD4I Abs). The research, conducted by Yale University, leverages the recent discovery of a new class of indoline CD4MCs that display improved antiviral potency and breadth...
This federal Project Grant award of $489,500 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to improve the targeting and elimination of the intact HIV reservoir. The key products of this 2-year project conducted by The Children's Hospital of Philadelphia Research Institute are: Identifying distinct transcriptional, epigenetic, and clonal features of CD4+ T cells with intact...